Lecap Asset Management Ltd. Purchases Shares of 6,815 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Lecap Asset Management Ltd. bought a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the third quarter, Holdings Channel.com reports. The firm bought 6,815 shares of the biopharmaceutical company’s stock, valued at approximately $499,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ITCI. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Intra-Cellular Therapies by 14.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 16,651 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 2,090 shares during the period. Wasatch Advisors LP grew its holdings in shares of Intra-Cellular Therapies by 6.3% during the 1st quarter. Wasatch Advisors LP now owns 3,854,747 shares of the biopharmaceutical company’s stock worth $266,748,000 after acquiring an additional 227,439 shares during the period. Privium Fund Management B.V. grew its holdings in shares of Intra-Cellular Therapies by 15.9% during the 1st quarter. Privium Fund Management B.V. now owns 108,883 shares of the biopharmaceutical company’s stock worth $7,535,000 after acquiring an additional 14,900 shares during the period. Fidelis Capital Partners LLC purchased a new position in shares of Intra-Cellular Therapies during the 1st quarter worth approximately $53,000. Finally, Jennison Associates LLC purchased a new position in shares of Intra-Cellular Therapies during the 1st quarter worth approximately $637,000. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Insider Activity

In other news, CEO Sharon Mates sold 34,396 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total transaction of $2,505,404.64. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, EVP Mark Neumann sold 18,714 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at approximately $2,229,876. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sharon Mates sold 34,396 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the transaction, the chief executive officer now directly owns 1,070,329 shares in the company, valued at approximately $77,962,764.36. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 175,316 shares of company stock valued at $13,037,345 in the last ninety days. 3.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ITCI. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Morgan Stanley upped their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada upped their price target on Intra-Cellular Therapies from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. Needham & Company LLC restated a “buy” rating and issued a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, August 7th. Finally, UBS Group cut their price target on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $96.62.

Intra-Cellular Therapies Trading Up 0.8 %

Shares of ITCI opened at $75.64 on Friday. The business’s fifty day simple moving average is $74.50 and its two-hundred day simple moving average is $72.69. Intra-Cellular Therapies, Inc. has a 12 month low of $45.50 and a 12 month high of $84.89. The company has a market cap of $7.99 billion, a price-to-earnings ratio of -65.21 and a beta of 1.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. The firm had revenue of $161.40 million for the quarter, compared to analysts’ expectations of $157.74 million. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company’s revenue was up 45.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.45) EPS. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.